At5g56700 Antibody

Gene and Protein Overview

The At5g56700 gene encodes a 398-amino-acid protein with FBD and LRR domains, suggesting involvement in protein-protein interactions (e.g., SCF E3 ubiquitin ligase complexes) or signal transduction pathways . The protein’s sequence includes regions critical for binding and structural stabilization, such as the N-terminal (MAKISDLSDELLVKILSFLPTKEAVSTSCLSKQWEFLWMWLSKLEFYFSDGSESACLRDFIAKNLPLHKAPIIESLRFCSFFGSLQPKDLKSWVRIAVSRCVRELSISLHDTTAAVSLPSSLYTCKSLVTLKLYGKKVLLDVPRTVFLPSLKTLQLERLRYSDEDSLRLLLSYCPVLEDLSIVREDYDNLRALVVIVPSLQRLSLEIPGNCSSDGYVIVTPSLKYFKVVDYRESMSYLIEQMPELEEADIVVLQYPEKLLESVTFFKRLSIRVIFNTYTETVYRDGIVFNRLENLKLCICNGDWSKLLIQFLKDSPNLRVLNLLVDDYPSSLGDYEPVRWKNNKSSVPKCLLESLETFEFAGYIGTPEERDFLSYIFKHARCLKSSSILSRPERYHGI) .

Applications in Research

The At5g56700 antibody is validated for:

• Western Blot (WB): Detects the ~50 kDa protein in A. thaliana lysates .

• Immunoprecipitation (IP): Potential for studying protein complexes, though specific data is limited .

• ELISA: Used for quantitative antigen detection (titer ≥10,000) .

Key Limitations:

• No published studies validate its use in immunohistochemistry (IHC) or immunofluorescence (IF).

• Cross-reactivity with homologous proteins in other species is uncharacterized .

Availability and Customization

Customization: Cusabio offers tailored antibody development for specific epitopes, blocking assays, or family cross-reactivity .

Validation Challenges

As highlighted in antibody validation initiatives , the At5g56700 antibody’s specificity and performance require rigorous testing:

• Target Binding: Confirm binding to At5g56700 in complex lysates (e.g., via KO cell lines).

• Cross-reactivity: Exclude off-target binding to related F-box/LRR proteins.

• Orthogonal Methods: Pair WB data with mass spectrometry or CRISPR-based knockout models .

Future Directions

• Functional Studies: Explore the antibody’s utility in blocking At5g56700 interactions (e.g., in ubiquitination assays).

• Epitope Mapping: Deconvolute monoclonal combinations to identify high-affinity clones .

• Collaborative Validation: Public repositories (e.g., DSHB) could standardize antibody performance data .